Mostrar o rexistro simple do ítem

dc.contributor.authorIsidro, María Luisa
dc.contributor.authorCordido, Fernando
dc.date.accessioned2023-05-02T07:43:09Z
dc.date.available2023-05-02T07:43:09Z
dc.date.issued2010-01-12
dc.identifier.citationIsidro ML, Cordido F. Approved and off-label uses of obesity medications, and potential new pharmacologic treatment options. Pharmaceuticals (Basel). 2010 Jan 12;3(1):125-145.es_ES
dc.identifier.issn1424-8247
dc.identifier.urihttp://hdl.handle.net/2183/32966
dc.descriptionReviewes_ES
dc.description.abstract[Abstract] Available anti-obesity pharmacotherapy options remain very limited and development of more effective drugs has become a priority. The potential strategies to achieve weight loss are to reduce energy intake by stimulating anorexigenic signals or by blocking orexigenic signals, and to increase energy expenditure. This review will focus on approved obesity medications, as well as potential new pharmacologic treatment options.es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.relation.urihttps://doi.org/10.3390/ph3010125es_ES
dc.rightsAtribución 3.0 Españaes_ES
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectDrug treatmentes_ES
dc.subjectGhrelines_ES
dc.subjectLeptines_ES
dc.subjectObesityes_ES
dc.subjectOrlistates_ES
dc.subjectSibutraminees_ES
dc.subjectRimonabantes_ES
dc.titleApproved and off-label uses of obesity medications, and potential new pharmacologic treatment optionses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessinfo:eu-repo/semantics/openAccesses_ES
UDC.journalTitlePharmaceuticalses_ES
UDC.volume3es_ES
UDC.issue1es_ES
UDC.startPage125es_ES
UDC.endPage145es_ES


Ficheiros no ítem

Thumbnail
Thumbnail

Este ítem aparece na(s) seguinte(s) colección(s)

Mostrar o rexistro simple do ítem